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‘It’s impossible to roll out antiretrovirals in 
Africa!’ I clearly remember hearing this on 
a daily basis while studying in Canada 13 
years ago. And there were strong points made: 
too expensive, not enough doctors, risk of 
resistance, how to monitor patients in resource-limited settings, 
and so forth. Thankfully, not everyone believed this and we 
advocated and pressured from all around the world, and the 
price of antiretroviral therapy (ART) did come down, by more 
than ten times. 
Ten years later, after studying medicine in the United 
Kingdom (UK), I moved to Mseleni Hospital in northern 
KwaZulu-Natal for my ‘voluntary community service’. The 
medical director of the hospital had been there for more 
than 30 years and started rolling out ART unlawfully before 
March 2004. He had developed some outreach clinics and 
managed to have his hospital very well staffed with local 
and international doctors. With some basic teaching in HIV 
and  tuberculosis (TB), we (the UK doctors) were very soon 
thrown into the deep end. The first three months of practising 
were a steep learning curve, particularly in HIV medicine. 
We were working in the outpatient department where AIDS 
patients often presented very late, and on the ward where we 
had very complex co-infected TB/HIV patients with poor 
referral systems. The mortality due to HIV/TB was often 
very high. Despite some HIV-positive patients still presenting 
very late (particularly men), we had good statistics on testing 
people and good prevention of mother-to-child transmission 
(PMTCT) coverage.
As part of my duties, I was visiting an outreach clinic weekly 
called Manaba Clinic. Most of my work there was to initiate 
patients on ART and to follow up problematic cases. I recall 
the particular case of a 9-year-old boy who had virological 
failure on ART, despite adherence reinforcement. After only 
a few months of working with HIV and ART, and without 
access to resistance testing, I felt quite out of my depth. 
Extraordinarily, however, I was able to get advice from an 
HIV specialist paediatrician in Cape Town within minutes 
via the national HIV hotline. Following his advice, I started 
the little boy on lamivudine (3TC) monotherapy as a bridging 
measure, while waiting for new paediatric formulations to be 
made available.
A few months later, I saw the same 9-year-old boy and 
his mother for a follow-up appointment. His viral load was 
now nearly suppressed and I was going to continue the 3TC 
monotherapy as per the advice I had received, when mum (via a 
translator) started objecting. She had always been told that her 
child must take three antiretrovirals, so why was he taking only 
one drug? Wasn’t there a risk of resistance? 
She made me realise how far we had come in ten years: ART 
was being rolled out to places hundreds of kilometres from 
the nearest city; patients with basic education were gaining a 
good understanding of a complex disease; and expert help from 
thousands of kilometres away was available within minutes over 
the phone. Against all odds, what a long way HIV treatment had 
come!
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‘ ... we advocated and 
pressured from all around the 
world, and the price of ART did 
come down, by more than ten 
times.’
‘She had always been told 
that her child must take three 
antiretrovirals, so why was he 
taking only one drug? Wasn’t 
there a risk of resistance?’
